Kavallaris M - Search Results

1

TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.

McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH, Shum MS, Byrne FL, Kavallaris M. McCarroll JA, et al. Among authors: kavallaris m. Cancer Res. 2015 Jan 15;75(2):415-25. doi: 10.1158/0008-5472.CAN-14-2740. Epub 2014 Nov 20. Cancer Res. 2015. PMID: 25414139

2

Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.

Norris MD, Haber M, Kavallaris M, Brian MJ, Lutze LH, White L, Stewart BW. Norris MD, et al. Among authors: kavallaris m. Cancer. 1991 Sep 1;68(5):981-7. doi: 10.1002/1097-0142(19910901)68:5<981::aid-cncr2820680512>3.0.co;2-w. Cancer. 1991. PMID: 1913492

3

Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.

Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW. Haber M, et al. Among authors: kavallaris m. Cancer Res. 1989 Oct 1;49(19):5281-7. Cancer Res. 1989. PMID: 2569932

4

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M. Kavallaris M, et al. Cancer Res. 2001 Aug 1;61(15):5803-9. Cancer Res. 2001. PMID: 11479219

5

Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions.

Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, Haber M, Kavallaris M. Verrills NM, et al. Among authors: kavallaris m. Chem Biol. 2003 Jul;10(7):597-607. doi: 10.1016/s1074-5521(03)00141-8. Chem Biol. 2003. PMID: 12890533

6

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M. Don S, et al. Among authors: kavallaris m. Mol Cancer Ther. 2004 Sep;3(9):1137-46. Mol Cancer Ther. 2004. PMID: 15367708

7

Acid-cleavable polymeric core-shell particles for delivery of hydrophobic drugs.

Chan Y, Bulmus V, Zareie MH, Byrne FL, Barner L, Kavallaris M. Chan Y, et al. Among authors: kavallaris m. J Control Release. 2006 Oct 10;115(2):197-207. doi: 10.1016/j.jconrel.2006.07.025. Epub 2006 Jul 29. J Control Release. 2006. PMID: 16996635

8

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M. Verrills NM, et al. Among authors: kavallaris m. J Natl Cancer Inst. 2006 Oct 4;98(19):1363-74. doi: 10.1093/jnci/djj372. J Natl Cancer Inst. 2006. PMID: 17018783

9

The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.

Liaw TY, Chang MH, Kavallaris M. Liaw TY, et al. Among authors: kavallaris m. Curr Drug Targets. 2007 Jun;8(6):739-49. doi: 10.2174/138945007780830836. Curr Drug Targets. 2007. PMID: 17584029 Review.

10

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.

Gan PP, Pasquier E, Kavallaris M. Gan PP, et al. Among authors: kavallaris m. Cancer Res. 2007 Oct 1;67(19):9356-63. doi: 10.1158/0008-5472.CAN-07-0509. Cancer Res. 2007. PMID: 17909044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters